prostate cancer

Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.

The finding points toward a new approach that directly targets the cancer’s fuel source.

In the age of Covid, Community Outreach & Engagement at DCI comes of age, team expands with disparities researcher/associate director

In an open letter, the NCCN, ACS, and major U.S. cancer centers, inc. DCI, urge public to resume cancer screening & treatment during pandemic.

As the COVID-19 pandemic shines a light on health disparities, efforts to find new ways to reduce them get a boost.

Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.

Kevin Oeffinger, MD, is guest co-editor of a new book covering colorectal, lung, cervical, prostate, skin cancer, and ovarian cancer screening.

DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.

Urologist Judd Moul, MD, presented and answered questions at “A No-nonsense Interactive discussion on Active Surveillance and Prostate Cancer."

The DCRI study is the first cardiovascular outcomes trial to compare two different types of cancer treatment.

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

Drug tested in lab studies halts cancer cells that are impervious to hormone therapy.

ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.

Andrew Armstrong, MD, found that treatment with enzalutamide and ADT significantly reduced the risk of metastasis or death over time in men with mHSPC.

Deputy Director of Duke Cancer Institute Steven Patierno, PhD, is energized by his decades-long work in cancer control and cancer health disparities.

When Robert “Bob” List, 73, a retired colonel with the U.S. Marine Corps, was diagnosed with stage 2 prostate cancer, he immediately began to research the “enemy” threat.

Black men are underrepresented in clinical trials for prostate cancer, despite an almost two-fold greater incidence and mortality of disease in black versus white populations.

Dan George, MD, remem­bers one of the first times he helped someone live longer. He was treating a patient with metastatic kidney can­cer.

Five years after surgery to treat prostate cancer, Steele Dewey of Charlotte, North Carolina was told that the cancer had spread. He chose Dan George, MD, at Duke.

When his dad passed away from cancer, Myles Owens IV launched a clothing line in his memory. Part of the proceeds benefit Duke Cancer Institute research.